Background: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alter central trigeminal pain processing; (ii) responders to galcanezumab treatment would show specific hypothalamic modulation in contrast to non-responders; and (iii) the ligand and the receptor antibody differ in brain responses.

Methods: Using an established trigeminal nociceptive functional magnetic imaging paradigm, 26 migraine patients were subsequently scanned twice: before and 2–3 weeks after administration of galcanezumab.

Results: We found that galcanezumab decreases hypothalamic activation in all patients and that the reduction was stronger in responders than in non-responders. Contrasting erenumab and galcanezumab showed that both antibodies activate a distinct network. We also found that pre-treatment activity of the spinal trigeminal nucleus (STN) and coupling between the STN and the hypothalamus covariates with the response to galcanezumab.

Conclusions: These data suggest that despite relative impermeability of the blood-brain barrier for CGRP mAb, mAb treatment induces certain and highly specific brain effects which may be part of the mechanism of their efficacy in migraine treatment.

Funding: This work was supported by the German Ministry of Education and Research (BMBF) of ERA-Net Neuron under the project code BIOMIGA (01EW2002 to AM) and by the German Research Foundation (SFB936-178316478-A5 to AM). The funding sources did not influence study conduction in any way. 

Clinical trial number: The basic science study was preregistered in the Open Science Framework (https://osf.io/m2rc6).

Direct link to the published dataset: https://datadryad.org/stash/dataset/doi:10.5061/dryad.w3r2280t2

Funding: Bundesministerium für Bildung und Forschung, Award: BIOMIGA (01EW2002 to AM); Deutsche Forschungsgemeinschaft, Award: SFB936- 178316478 - A5 (AM)

{"references": ["Hauke Basedau, Lisa-Marie Sturm, Jan Mehnert, Kuan-Po Peng, Marlene Schellong, Arne May (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target \u2013 an fMRI study eLife 11:e77146 https://doi.org/"]}